US-based Trovagene has developed a urine-based molecular diagnostic test to detect and monitor cancer mutations. The test quantitatively detects KRAS mutations in transrenal DNA,which may be originated from both normal and diseased cells. ...
Tags: Trovagene, molecular diagnostic test, cancer mutations, cancer monitoring